Knowledge mapping of immunotherapy for allergic rhinoconjunctivitis: a bibliometric study (2002–2021)

Main Article Content

Na Chen
Kun Zhang
Youwei Li
Ying Liu


Allergic rhinoconjunctivitis, bibliometric study, CiteSpace, immunotherapy


Background: Allergic rhinoconjunctivitis (ARC) is a common chronic inflammatory disease. Numerous studies on the treatment of ARC have been published. By contrast, there are few bibliometric studies on immunotherapy for ARC. The purpose of this article is to describe the current treatments for ARC and to identify the trends in immunotherapy for ARC.

Methods: Publications were searched from the Web of Science (WOS) Core Collection on April 25, 2022. CiteSpace and Microsoft Excel software were used for further bibliometric analysis.

Results: A total of 969 publications on immunotherapy for ARC in English were retrieved. The number of relevant publications has been continuously increasing over the past 20 years, with many of the publications coming from Germany and the United States of America. In terms of institutions, the ALK Company in Denmark, Imperial College London in United Kingdom, and Charite–Universitatsmedizin Berlin in Germany published the most articles on immunotherapy for ARC. Meanwhile, Allergy and Journal of Allergy and Clinical Immunology published the most number of studies, and Oliver Pfaar from Germany authored the most number of articles. “Subcutaneous immunotherapy,” “international consensus,” “allergen immunotherapy,” and “recommendation” were the most popular subjects. Thus, directions in research can be predicted as studies regarding mechanisms of ARC, clinical trials, and extracts have reported high-quality results.

Conclusion: Over the past 20 years, the overall quality of research on immunotherapy for ARC has gradually improved, allowing the introduction of specific and targeted treatment. Currently, the main focus of ARC research is the novel routes of drug delivery and combined treatment with biological agents.

Abstract 106 | PDF Downloads 85 HTML Downloads 9 XML Downloads 2


1. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43. 10.1016/S0140-6736(06)69283-0

2. Naclerio RM. Allergic rhinitis. N Engl J Med. 1991;325(12): 860–9. 10.1056/NEJM199109193251206

3. Patel DS, Arunakirinathan M, Stuart A, Angunawela R. Allergic eye disease. BMJ. 2017;359:j4706. 10.1136/bmj.j4706

4. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112–22. 10.1016/S0140-6736(11)60130-X

5. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, Gerth van Wijk R, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4): 765–98. 10.1111/all.13317

6. Drazdauskaitė G, Layhadi JA, Shamji MH. Mechanisms of allergen immunotherapy in allergic rhinitis. Curr Allergy Asthma Rep. 2020;21(1):2. 10.1007/s11882-020-00977-7

7. Berings M, Karaaslan C, Altunbulakli C, Gevaert P, Akdis M, Bachert C, et al. Advances and highlights in allergen immunotherapy: on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol. 2017;140(5):1250–67. 10.1016/j.jaci.2017.08.025

8. Bachmann MF, Kündig TM. Allergen-specific immunotherapy: is it vaccination against toxins after all? Allergy. 2017;72(1): 13–23. 10.1111/all.12890

9. Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial. J Allergy Clin Immunol. 2021;147(3):1011–9. 10.1016/j.jaci.2020.07.002

10. Sun W, Huang P, Song H, Feng D. Bibliometric analysis of acute pancreatitis in web of science database based on CiteSpace software. Medicine. 2020;99(49):e23208. 10.1097/MD.0000000000023208

11. Ma D, Yang B, Guan B, Song L, Liu Q, Fan Y, et al. A bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol. 2021;12:731933. 10.3389/fimmu.2021.731933

12. Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Canonica GW, Merk H, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65(12):1525–30. 10.1111/j.1398-9995.2010.02474.x

13. Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, van Wijk RG, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765–98. 10.1111/all.13317

14. Tsabouri S, Mavroudi A, Feketea G, Guibas GV. Subcutaneous and sublingual immunotherapy in allergic asthma in children. Front Pediatr. 2017;5:82. 10.3389/fped.2017.00082

15. Liu X, Ng CL, Wang Y. The efficacy of sublingual immunotherapy for allergic diseases in Asia. Allergol Int. 2018;67(3): 309–19. 10.1016/j.alit.2018.02.007

16. Hylander T, Larsson O, Petersson-Westin U, Eriksson M, Georén SK, Winqvist O, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo--controlled trial. Respir Res. 2016;17:10. 10.1186/s12931-016-0324-9

17. Ryan D, Gerth van Wijk R, Angier E, Kristiansen M, Zaman H, Sheikh A, et al. Challenges in the implementation of the EAACI AIT guidelines: a situational analysis of current provision of allergen immunotherapy. Allergy. 2018;73(4):827–36. 10.1111/all.13264

18. Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial. J Allergy Clin Immunol. 2021;147(3):1011–9. 10.1016/j.jaci.2020.07.002

19. Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71–84. 10.1007/82_2011_133

20. Patterson AM, Bonny AE, Shiels WE 2nd, Erwin EA. Three-injection intralymphatic immunotherapy in adolescents and young adults with grass pollen rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2016;116(2):168–70. 10.1016/j.anai.2015.11.010

21. Senti G, Freiburghaus AU, Larenas-Linnemann D, Hoffmann HJ, Patterson AM, Klimek L, et al. Intralymphatic immunotherapy: update and unmet needs. Int Arch Allergy Immunol. 2019;178(2):141–9. 10.1159/000493647

22. Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132(5):1248–52. 10.1016/j.jaci.2013.07.033

23. Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Ann Allergy Asthma Immunol. 2018;121(3):293–305. 10.1016/j.anai.2018.07.014

24. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109(2):274–80. 10.1067/mai.2002.121949

25. Başer E, Degirmenci PB, Arslan IB, Cukurova I. Effect of omalizumab on nasal symptoms in asthma and perennial allergic rhinitis. J Coll Physicians Surg Pak. 2020;30(11):1170–4. 10.29271/jcpsp.2020.11.1170

26. Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergol Int. 2020;69(2):167–77. 10.1016/j.alit.2020.01.004

27. Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol. 2014;133(3):937. 10.1016/j.jaci.2013.12.1089

28. Kawakami T, Blank U. From IgE to omalizumab. J Immunol. 2016;197(11):4187–92. 10.4049/jimmunol.1601476

29. Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6. 10.1067/mai.2002.121317

30. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term-preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8. 10.1111/j.1398-9995.2007.01451.x

31. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117(4):802–9. 10.1016/j.jaci.2005.12.1358

32. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116(3):608–13. 10.1016/j.jaci.2005.06.004

33. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120(6):1338–45. 10.1016/j.jaci.2007.07.046

34. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7. 10.1016/j.jaci.2004.07.012

35. Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(8): 1301–9. 10.1001/jamainternmed.2015.2840

36. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25. 10.1016/j.jaci.2011.12.973

37. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. AAO-HNSF. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015; 152(1 Suppl):S1–43. 10.1177/0194599814561600

38. Enrique E, Pineda F, Malek T, Bartra J, Basagaña M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–9. 10.1016/j.jaci.2005.08.027